LadRx

LadRx Corporation is a biopharmaceutical R&D company focused on oncology. LadRx's oncology pipeline concentrates on the clinical development of Aldoxorubicin (previously known as INNO-206), an improved version of the widely used chemotherapy agent doxorubicin. LadRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcoma, has completed its primary Phase 1b/2 clinical trial with the same indication, and has launched a Phase 1b pharmacokinetic clinical trial in patients with metastatic solid tumors and a Phase 1b study of Aldoxorubicin in combination with doxorubicin for patients with advanced solid tumors. The company is commencing a pivotal Phase 3 trial under a Special Protocol Assessment (SPA), where Aldoxorubicin is being evaluated as a treatment for patients with soft tissue sarcoma whose tumors have progressed following chemotherapy. LadRx is expanding its oncology candidate pipeline based on a novel linker platform technology that can be utilized with various chemotherapeutic agents and allows for higher drug concentrations at tumor sites. The company also holds rights to two additional drug candidates: tamibarotene and bafetinib. LadRx has completed the evaluation of bafetinib in the ENABLE Phase 2 clinical trial for high-risk B-cell chronic lymphocytic leukemia (B-CLL) and plans to seek partnerships for further development of bafetinib, while also assessing the further development of tamibarotene.